ライフサイエンスコーパス: hepatorenal syndrome

1 rolled trials done in 739 adults with type 1 hepatorenal syndrome.

2 a, and its associated complications, such as hepatorenal syndrome.

3 diuretics for ascites, and terlipressin for hepatorenal syndrome.

4 acute kidney injury are discussed, including hepatorenal syndrome.

5 ompared with placebo in patients with type 1 hepatorenal syndrome.

6 f different management strategies for type 1 hepatorenal syndrome.

7 plus octreotide with albumin for reversal of hepatorenal syndrome.

8 ompared with placebo in patients with type 1 hepatorenal syndrome.

9 , bacterial infection, and/or development of hepatorenal syndrome.

10 albumin and survival in patients with type 1 hepatorenal syndrome.

11 is useful in the management of patients with hepatorenal syndrome.

12 ut also heart failure in the pathogenesis of hepatorenal syndrome.

13 rome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

14 by the presence of hepatic encephalopathy or hepatorenal syndrome.

15 o the prevention and effective treatment for hepatorenal syndrome.

16 ewer patients receiving colchicine developed hepatorenal syndrome.

17 ctiveness and safety in patients with type 1 hepatorenal syndrome.

18 serum creatinine and are more likely to have hepatorenal syndrome.

19 , ascites, encephalopathy, coagulopathy, and hepatorenal syndrome.

20 s of IAH may also be seen in cardiorenal and hepatorenal syndromes.

21 Patients with sepsis (1.24 [1.23-1.25]), hepatorenal syndrome (1.22 [1.21-1.22]), and peritonitis

22 A higher proportion of patients on NSBBs had hepatorenal syndrome (24% vs 11% in those not taking NSB

23 a (68.6 %), acute tubular necrosis (25.7 %), hepatorenal syndrome (5.7 %), respectively.

24 (HE; 37.8%), variceal bleeding (VB; 17.5%), hepatorenal syndrome (6.3%), and spontaneous bacterial p

25 Extreme renal vasoconstriction characterizes hepatorenal syndrome, a functional and potentially rever

26 y, alcohol-related liver disease can lead to hepatorenal syndrome, a severe type of kidney dysfunctio

27 t study using this shunt in the treatment of hepatorenal syndrome, a trial of antibiotic prophylaxis

28 Terlipressin reverses hepatorenal syndrome-acute kidney injury (HRS-AKI) by in

29 Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with

30 reversal of hepatorenal syndrome, relapse of hepatorenal syndrome after initial reversal, and adverse

31 re effective at treating acute kidney injury-hepatorenal syndrome (AKI-HRS), liver transplantation (L

32 to terlipressin and albumin in patients with hepatorenal syndrome-AKI (HRS-AKI), and (3) predicting i

33 Search terms included: hepatorenal syndrome; albumin; vasoconstrictor; terlipre

34 ised, time of hospitalization, and risks for hepatorenal syndrome and acute kidney injury.

35 with secondary end points of development of hepatorenal syndrome and response to therapy based on th

36 re two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and type 2 hepatorenal syndrome.

37 o further decompensation (variceal bleeding, hepatorenal syndrome) and improves survival.

38 No patient developed hepatorenal syndrome, and 1-year survival of 67% was bet

39 group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1

40 ores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.

41 to high rates of acute kidney injury (AKI), hepatorenal syndrome, and mortality.

42 atment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).

43 0 days; incidence of infection, incidence of hepatorenal syndrome, and proportion of participants wit

44 ch as variceal bleeding, encephalopathy, and hepatorenal syndrome, and sociodemographic factors, such

45 objective criteria of severity and recoding hepatorenal syndrome as a particular form of renal dysfu

46 Hepatorenal syndrome as the sole primary etiology of kid

47 t in native kidney function follows SLK, and hepatorenal syndrome as the sole primary etiology of kid

48 The cumulative incidence of hepatorenal syndrome at 6 months was not significantly d

49 sin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use i

50 tudied to improve outcomes for patients with hepatorenal syndrome, but trials have reported variable

51 Otherwise, hepatorenal syndrome carries a high mortality.

52 rrhotic patients with RF, in particular with hepatorenal syndrome, CLKT is preferable to LTA because

53 Recommended treatment for type 1 hepatorenal syndrome consists of albumin and vasoconstri

54 sociated with time-dependent change in eGFR, hepatorenal syndrome, dialysis requirement, hepatitis C,

55 gth of stay was associated with eGFR at OLT, hepatorenal syndrome, dialysis requirement, model for en

56 h as restless leg syndrome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

57 n methods for the treatment or prevention of hepatorenal syndrome except to maintain adequate hemodyn

58 erlipressin improved the rate of reversal of hepatorenal syndrome from 39% to 18%.

59 adrenaline-treated patients with reversal of hepatorenal syndrome had recurrence on discontinuation o

60 In patients with hepatorenal syndrome, hemodialysis can be used as a brid

61 The percentages of patients who developed hepatorenal syndrome, hepatic encephalopathy, or sepsis

62 rmed in case of different conditions such as hepatorenal syndrome, hepatichydrothorax, portal vein th

63 cterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, hypoglyc

64 Hepatorenal syndrome, hepatocellular carcinoma, variceal

65 disposes the patient to variceal hemorrhage, hepatorenal syndrome, hepatopulmonary syndrome, and unco

66 evels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for

67 Secondary outcomes included hepatorenal syndrome (HR, 0.47 [95% CI, 0.40-0.56]), spo

68 re sepsis (27% versus 9%, P = 0.003), type-1 hepatorenal syndrome (HRS) (16% versus 3%, P = 0.002), a

69 with acute tubular necrosis (ATN) (n = 10), hepatorenal syndrome (HRS) (n = 18), and prerenal azotem

70 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS) and esophageal variceal hemor

71 Hepatorenal syndrome (HRS) carries a high short-term mor

72 Type-1 hepatorenal syndrome (HRS) is a common complication of b

73 Hepatorenal syndrome (HRS) is a form of kidney dysfuncti

74 Hepatorenal syndrome (HRS) is a rare and highly morbid f

75 Hepatorenal syndrome (HRS) is a serious complication of

76 Hepatorenal syndrome (HRS) is associated with high rates

77 nd albumin (triple therapy) is used to treat hepatorenal syndrome (HRS) often as a bridge to liver tr

78 Hepatorenal syndrome (HRS) type 1 is a progressive funct

79 Fourteen patients with LVDD developed hepatorenal syndrome (HRS) type 1 on follow-up.

80 e prerenal AKI), acute tubular necrosis, and hepatorenal syndrome (HRS), a functional type of prerena

81 The hepatorenal syndrome (HRS), a progressive but potentiall

82 Hepatorenal syndrome (HRS), a serious complication of ci

83 edict development of renal dysfunction (RD), hepatorenal syndrome (HRS), ACLF, and mortality.

84 s including hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

85 plications [hepatic encephalopathy, ascites, hepatorenal syndrome (HRS), and esophageal variceal hemo

86 holipid syndrome (APLS), ESLD complicated by hepatorenal syndrome (HRS), and severe CAD who successfu

87 In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used e

88 mia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS).

89 nally may be done for the renal diagnosis of hepatorenal syndrome (HRS).

90 oconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world

91 ctors and albumin is used in the reversal of hepatorenal syndrome (HRS-AKI), the most lethal complica

92 dney injury (AKI) in cirrhosis, particularly hepatorenal syndrome (HRS-AKI).

93 231 (62%) had pre-renal AKI; 61 (16.4%) had hepatorenal syndrome (HRS-AKI); 25 (6.7%) had HRS-AKD; 3

94 2 situations within AKI (ie, with or without hepatorenal syndrome [HRS]), only HRS-AKI remained assoc

95 ncephalopathy, variceal hemorrhage [VH], and hepatorenal syndrome [HRS]).

96 Hepatorenal syndrome, HRS, is a diagnosis of exclusion.

97 Type 2 hepatorenal syndrome (HRS2) is a functional renal impair

98 The development of hepatorenal syndrome in liver cirrhosis leads to an incr

99 ntaneous bacterial peritonitis is 11% and of hepatorenal syndrome is 8%; the latter is associated wit

100 Hepatorenal syndrome is a significant cause of acute kid

101 ients with acute liver failure (ALF) in whom hepatorenal syndrome is common.

102 avenous albumin therapy for the treatment of hepatorenal syndrome is ongoing with a growing body of r

103 iceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome), liver transplant, and liver-relat

104 Hepatorenal syndrome may improve by increasing renal blo

105 oup (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopat

106 rgoing large-volume paracentesis or who have hepatorenal syndrome or spontaneous bacterial peritoniti

107 alopathy, ascites, hepatocellular carcinoma, hepatorenal syndrome, or bleeding caused by portal hyper

108 ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, or fulminant hepatic failure.

109 k of hospital death in patients with sepsis, hepatorenal syndrome, or peritonitis warrants further in

110 of hepatic encephalopathy, ascites, varices, hepatorenal syndrome, or spontaneous bacterial peritonit

111 er cancer, receipt of liver transplantation, hepatorenal syndrome, prolonged length of stay, and hosp

112 Secondary outcomes were reversal of hepatorenal syndrome, relapse of hepatorenal syndrome af

113 The hepatorenal syndrome represents the result of extreme va

114 The hepatorenal syndrome represents the result of extreme va

115 Hyponatremia and the hepatorenal syndrome result from water retention and ren

116 A meta-analysis was performed of hepatorenal syndrome reversal and survival in relation t

117 The pooled percentage of patients achieving hepatorenal syndrome reversal was 49.5% (95% confidence

118 significant increase of similar magnitude in hepatorenal syndrome reversal was also observed (odds ra

119 Neither survival nor hepatorenal syndrome reversal was significantly affected

120 ions, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT =

121 CLKT patients with hepatorenal syndrome showed significantly higher patient

122 sode and secondary prophylaxis), ascites and hepatorenal syndrome, spontaneous bacterial peritonitis

123 cations (hyponatremia, hepatic hydrothorax), hepatorenal syndrome, spontaneous bacterial peritonitis,

124 ), portal hypertensive gastropathy, ascites, hepatorenal syndrome, spontaneous bacterial peritonitis,

125 ars) with decompensated cirrhosis and type 1 hepatorenal syndrome that compared the efficacy of activ

126 peritonitis, in acute kidney injury, and in hepatorenal syndrome, the amount and schedule of albumin

127 Clinical studies of type 1 hepatorenal syndrome treatment with albumin and vasocons

128 Hepatorenal syndrome type 1 (HRS-1) in patients with cir

129 Hepatorenal syndrome type 1 (HRS-1) is a severe form of

130 Hepatorenal syndrome type 1 (HRS-1), which is a specific

131 There are two forms of hepatorenal syndrome: type 1 hepatorenal syndrome and ty

132 included other specific liver diagnoses (eg, hepatorenal syndrome), viral hepatitis, and hepatobiliar

133 nd reversible causes of renal failure (i.e., hepatorenal syndrome), whereas combined liver and kidney

134 ect a significant difference in incidence of hepatorenal syndrome, which was less frequent in the gro

135 de (OR 26.25, 95% CI 3.07-224.21) to reverse hepatorenal syndrome, with low-quality evidence supporti